Literature DB >> 14624789

FDG PET imaging in hereditary thyroid cancer.

A Boér1, S Szakáll, I Klein, M Kásler, B Vincze, L Trón, M Godény, H Herzog, I Péter, O Esik.   

Abstract

AIM: To report the role of different imaging methods in staging individuals with multiple endocrine neoplasia 2A (MEN2A) or familial medullary thyroid carcinoma (FMTC).
MATERIAL AND METHODS: Fourteen newly diagnosed gene carriers underwent cervical ultrasound scanning (US), cervical and mediastinal CT, MRI and whole-body meta-[131I]iodobenzylguanidine (MIBG) scintigraphy and [18F]fluorodeoxyglucose (FDG) PET scanning.
RESULTS: US identified seven true primary cancer. CT and MRI located only tumors > or =5 mm in diameter. MIBG scintigraphy and FDG PET could not identify MTC foci within the thyroid. Whole-body FDG PET identified two true-positive and one false-positive lymph node metastases. MIBG scintigraphy did not identify lymph node metastases. Total thyroidectomy was performed in 12 cases, and subtotal thyroidectomy in two subjects.
CONCLUSIONS: Whole-body FDG PET and cervical US help stage individuals carrying mutant genes verifying MEN2A or FMTC.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14624789     DOI: 10.1016/s0748-7983(03)00137-9

Source DB:  PubMed          Journal:  Eur J Surg Oncol        ISSN: 0748-7983            Impact factor:   4.424


  4 in total

Review 1.  Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 fluorodeoxyglucose positron emission tomography: a meta-analysis.

Authors:  Giorgio Treglia; Maria Felicia Villani; Alessandro Giordano; Vittoria Rufini
Journal:  Endocrine       Date:  2012-04-17       Impact factor: 3.633

Review 2.  Artificial Intelligence in Medical Imaging and its Impact on the Rare Disease Community: Threats, Challenges and Opportunities.

Authors:  Navid Hasani; Faraz Farhadi; Michael A Morris; Moozhan Nikpanah; Arman Rhamim; Yanji Xu; Anne Pariser; Michael T Collins; Ronald M Summers; Elizabeth Jones; Eliot Siegel; Babak Saboury
Journal:  PET Clin       Date:  2022-01

Review 3.  18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.

Authors:  Sona Balogova; Jean-Noël Talbot; Valérie Nataf; Laure Michaud; Virginie Huchet; Khaldoun Kerrou; Françoise Montravers
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-02-16       Impact factor: 9.236

4.  PET Imaging in Recurrent Medullary Thyroid Carcinoma.

Authors:  Giorgio Treglia; Vittoria Rufini; Massimo Salvatori; Alessandro Giordano; Luca Giovanella
Journal:  Int J Mol Imaging       Date:  2012-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.